Literature DB >> 32373275

An Atypical and Multifactorial Acute Immune Polyradiculopathy: A Case Report.

Matthew R Brier1, Elyse A Everett1, Robert C Bucelli1.   

Abstract

Clinical diagnosis often focuses on identifying the single cause of a patient's symptoms but it is becoming increasingly recognized that a subset of patients exist where 2 pathological entities coexist. These patients present a particular diagnostic challenge because the first "positive" diagnostic test is not the definitive stopping point in their evaluation. Here, we present the case of a 47-year-old woman with multiple cranial neuropathies and a polyradiculopathy. A significant pleocytosis in the cerebrospinal fluid sparked a broad evaluation which revealed pathologic evidence of sarcoidosis and molecular evidence of neurofascin (NF)-155 and NF-140 antibodies. The pathogenic contribution of these 2 pathologic entities, or interaction, to this patient's case is not clear. Nevertheless, the patient responded robustly to steroids and symptoms significantly improved. This case is a demonstration of the balance between Occam's razor and Hickam's dictum in clinical practice.
© The Author(s) 2019.

Entities:  

Keywords:  cranial neuropathy; neurofascin; polyradiculopathy; sarcoid

Year:  2019        PMID: 32373275      PMCID: PMC7191666          DOI: 10.1177/1941874419865640

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  13 in total

1.  FDG PET findings leading to diagnosis of neurosarcoidosis.

Authors:  S Bartels; L Kyavar; N Blumstein; T Görg; S C Glöckner; R Zimmermann; J G Heckmann
Journal:  Clin Neurol Neurosurg       Date:  2012-04-13       Impact factor: 1.876

2.  A case of anti-neurofascin 155 antibody-positive combined central and peripheral demyelination successfully treated with plasma exchange.

Authors:  Mikito Shimizu; Tohru Koda; Yuji Nakatsuji; Hidenori Ogata; Jun-Ichi Kira; Hideki Mochizuki
Journal:  Rinsho Shinkeigaku       Date:  2016-12-23

3.  Neurosarcoidosis presenting as Guillain-Barré-like syndrome. A case report and review of the literature.

Authors:  Firas Fahoum; Vivian E Drory; Josephine Issakov; Miri Y Neufeld
Journal:  J Clin Neuromuscul Dis       Date:  2009-09

4.  Neurofascin as a target for autoantibodies in peripheral neuropathies.

Authors:  Judy King Man Ng; Joachim Malotka; Naoto Kawakami; Tobias Derfuss; Mohsen Khademi; Tomas Olsson; Christopher Linington; Masaaki Odaka; Björn Tackenberg; Harald Prüss; Jan M Schwab; Lutz Harms; Hendrik Harms; Claudia Sommer; Matthew N Rasband; Yael Eshed-Eisenbach; Elior Peles; Reinhard Hohlfeld; Nobuhiro Yuki; Klaus Dornmair; Edgar Meinl
Journal:  Neurology       Date:  2012-10-24       Impact factor: 9.910

Review 5.  Neurosarcoidosis: presentations and management.

Authors:  Vitaly Terushkin; Barney J Stern; Marc A Judson; Mari Hagiwara; Bidyut Pramanik; Miguel Sanchez; Stephen Prystowsky
Journal:  Neurologist       Date:  2010-01       Impact factor: 1.398

6.  Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.

Authors:  Jérôme J Devaux; Yumako Miura; Yuki Fukami; Takayuki Inoue; Constance Manso; Maya Belghazi; Kenji Sekiguchi; Norito Kokubun; Hiroo Ichikawa; Anna Hiu Yi Wong; Nobuhiro Yuki
Journal:  Neurology       Date:  2016-02-03       Impact factor: 9.910

7.  Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy.

Authors:  Hidenori Ogata; Ryo Yamasaki; Akio Hiwatashi; Nobuyuki Oka; Nobutoshi Kawamura; Dai Matsuse; Motoi Kuwahara; Hidekazu Suzuki; Susumu Kusunoki; Yuichi Fujimoto; Koji Ikezoe; Hitaru Kishida; Fumiaki Tanaka; Takuya Matsushita; Hiroyuki Murai; Jun-Ichi Kira
Journal:  Ann Clin Transl Neurol       Date:  2015-09-11       Impact factor: 4.511

8.  Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies.

Authors:  Elisabeth Burnor; Li Yang; Hao Zhou; Kristina R Patterson; Colin Quinn; Mary M Reilly; Alexander M Rossor; Steven S Scherer; Eric Lancaster
Journal:  Neurology       Date:  2017-11-29       Impact factor: 9.910

9.  Neurofascin as a novel target for autoantibody-mediated axonal injury.

Authors:  Emily K Mathey; Tobias Derfuss; Maria K Storch; Kieran R Williams; Kimberly Hales; David R Woolley; Abdulmonem Al-Hayani; Stephen N Davies; Matthew N Rasband; Tomas Olsson; Anja Moldenhauer; Sviataslau Velhin; Reinhard Hohlfeld; Edgar Meinl; Christopher Linington
Journal:  J Exp Med       Date:  2007-09-10       Impact factor: 14.307

10.  Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

Authors:  Luis Querol; Ricard Rojas-García; Jordi Diaz-Manera; Joseba Barcena; Julio Pardo; Angel Ortega-Moreno; Maria Jose Sedano; Laia Seró-Ballesteros; Alejandra Carvajal; Nicolau Ortiz; Eduard Gallardo; Isabel Illa
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.